Skip to main content

Table 3 Comparison with other studies which evaluate the out-of-hospital impact of changes in a hospital drug formulary

From: Impact of a change of bronchodilator medications in a hospital drug formulary on intra- and out-of-hospital drug prescriptions: interrupted time series design with comparison group

Author/yearCountrySettingTherapeutic groupMethodologyPre-/post-intervention periodOther contextual factorsEffect
Vázquez-Mourelle et al./2017 [16]SpainPublic district hospitalPPIsInterrupted time series analysis1 January 2013/31 December 2015 (36 months)
Inclusion of omeprazole
NoneImmediate reduction in pantoprazole in hospital outpatient clinics and long-term reduction in primary care. Sharp and long-term rise in the percentage of omeprazole over total PPIs in hospital out-patient units and primary care respectively.
Vázquez-Mourelle et al./2019 [17]SpainPublic tertiary university teaching hospitalLMWHInterrupted time series analysis with control group1 January 2011/31 December 2016 (72 months)
Withdrawal of bemiparin and dalteparin
Restriction on use of tinzaparin
Maintenance of enoxaparin
NoneImmediate significant reduction of 55.6% in the medication that was withdrawn and a 9.0% reduction in the medication that was restricted. Immediate 32.6% increase in the drug retained as freely prescribable.
Gallini et al./2013 [14]FranceNational health systemSerotonin antagonists
LMWH
EPO
PPIs
ACE inhibitors
ARBs
Statins
AAAs
SSRIs
Ecological study of spatial clusters, analysed by multivariate linear regression with instrumental variables.NA (cross sectional)NonePositive influence of hospital-prescribed medications on community prescriptions. This influence varied, both with drug class, proving stronger in the classes used for the cardiovascular system, and with hospital size.
Larsen et al./2014 [15]DenmarkPublic tertiary university teaching hospitalPPIs (policy of replacing an expensive PPI (esomeprazole) with less expensive PPIs)Pre-post, descriptive statistics in exact numbers and percentages1 January 2009/31 December 2010 (policy change: switch to using a less expensive PPI)Esomeprazole was offered to hospital with a 90% discount, which was an expensive PPI out-of-hospital.The probability of having an expensive PPI after hospitalisation decreased from 13.4 to 6.5%, while use of recommended PPIs increased.
  1. LMWH low molecular weight heparins, EPO erythropoietin, PPIs proton pump inhibitors, ACE inhibitors angiotensin-converting enzyme antagonists inhibitors, ARBs angiotensin-receptor blockers, AAAs alpha-adrenoreceptor antagonists, SSRIs selective serotonin re-uptake inhibitors